These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17521228)

  • 1. Oral disease-modifying treatments for multiple sclerosis: the story so far.
    Kieseier BC; Wiendl H
    CNS Drugs; 2007; 21(6):483-502. PubMed ID: 17521228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of multiple sclerosis.
    Meuth SG; Bittner S; Wiendl H
    Acta Neuropsychiatr; 2009 Jun; 21 Suppl 2():27-34. PubMed ID: 25384864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.
    Wiendl H; Kieseier BC
    Expert Opin Investig Drugs; 2003 Apr; 12(4):689-712. PubMed ID: 12665424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging oral drugs for multiple sclerosis.
    Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of multiple sclerosis therapy.
    Kieseier BC; Wiendl H; Hartung HP; Stüve O
    Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and treatment trials in multiple sclerosis.
    Kieseier BC; Wiendl H; Hemmer B; Hartung HP
    Curr Opin Neurol; 2007 Jun; 20(3):286-93. PubMed ID: 17495622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging multiple sclerosis oral therapies.
    Rammohan KW; Shoemaker J
    Neurology; 2010 Jan; 74 Suppl 1():S47-53. PubMed ID: 20038763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
    Thöne J; Ellrichmann G
    Drug Healthc Patient Saf; 2013; 5():37-47. PubMed ID: 23459383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.
    Warnke C; Kieseier BC; Hartung HP
    J Neural Transm (Vienna); 2013 Sep; 120 Suppl 1():S55-60. PubMed ID: 23793997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in multiple sclerosis, Part 1.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Sep; 52(18):1985-2000. PubMed ID: 8528866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
    Menge T; Weber MS; Hemmer B; Kieseier BC; von Büdingen HC; Warnke C; Zamvil SS; Boster A; Khan O; Hartung HP; Stüve O
    Drugs; 2008; 68(17):2445-68. PubMed ID: 19016573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.